Premium
Can Fite BioPharma Ltd (CANF)
AMEX
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III t... Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Show more
Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Can-Fite...
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30...
RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.16 | -10.4575163399 | 1.53 | 1.5499 | 1.36 | 80153 | 1.43714697 | CS |
| 4 | -0.29 | -17.4698795181 | 1.66 | 1.66 | 1.36 | 94726 | 1.53104287 | CS |
| 12 | -0.63 | -31.5 | 2 | 2.35 | 1.29 | 493380 | 1.59847198 | CS |
| 26 | -1.26 | -47.9087452471 | 2.63 | 3.12 | 1.29 | 268111 | 1.74337218 | CS |
| 52 | -0.71 | -34.1346153846 | 2.08 | 4.69 | 1.29 | 164504 | 1.97575746 | CS |
| 156 | -9.63 | -87.5454545455 | 11 | 12.9 | 1.29 | 141222 | 5.70233438 | CS |
| 260 | -19.83 | -93.5377358491 | 21.2 | 43.9 | 1.29 | 708381 | 20.12679 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 26,33 (-4,91%) | 87,91M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,8796 (2,97%) | 80,97M |
| FXIiShares China Large Cap | US$ 32,735 (1,41%) | 73,25M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,85 (7,14%) | 67,49M |
| ETHU2x Ether ETF | US$ 4,083 (-10,26%) | 53,99M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
